The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 4, 1999, Pages 377-381

  Villikka, Kirsti ^a   Kivistö, Kari T ^b   Neuvonen, Pertti J ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ONDANSETRON; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033046457     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70130-X     Document Type: Article

References (14)

1. 1. Roila F, Favero AD. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995;29:95-109.
2. 2. Pritchard JF. Ondansetron metabolism and pharmacokinetics. Semin Oncol 1992;19(suppl 10):9-15.
3. 3. Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995;23: 1225-30.
4. 4. Fischer V, Vickers AEM, Heitz F, Mahadevan S, Baldeck JP, Minery P, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytrypiamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994;22:269-74.
5. 5. Ashibrth EIL, Palmer JL, Bye A, Bedding A. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br J Clin Pharmacol 1994;37:389-91.
6. 6. Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, et al. Metabolism of cyclosporin A; IV: purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989;17:197-207.
7. 7. Grunberg SM, Groshen S, Robinson DC, Stevenson LL, Sanderson PE. Correlation of anti-emetic efficacy and plasma levels of ondansetron. Eur J Cancer 1990;26: 879-82.
8. 8. Pritchard JF, Wells CD. Relationships between ondansetron systemic exposure and antiemetic efficacy and safety in cancer patients receiving cisplatin. Pharmacology 1992;45:188-94.
9. 9. Liu J, Stewart JT. High-performance liquid chromatographic analysis of ondansetron enantiomers in human serum using a reversed-phase cellulose-based chiral stationary phase and solid-phase extraction. J Chromatogr B 1997;694:179-84.
10. 10. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. The nifedipine-rifampin interaction: evidence for induction of gut wall metabolism. Drug Metab Dispos 1996;24:1121-3.
11. 11. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996;24:796-801.
12. 12. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7.
13. 13. Figg WD, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson SW, et al. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J Clin Pharmacol 1996;36:206-15.
14. 14. Britto MR, Hussey EK, Mydlow P, Powell JR, Brouwer KLR. Effect of enzyme inducers on ondansetron metabolism in humans [abstract]. Clin Pharmacol Ther 1997; 61:228.